A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
Abstract Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to it...
Guardado en:
Autores principales: | Masaya Igase, Yuki Nemoto, Kazuhito Itamoto, Kenji Tani, Munekazu Nakaichi, Masashi Sakurai, Yusuke Sakai, Shunsuke Noguchi, Masahiro Kato, Toshihiro Tsukui, Takuya Mizuno |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7ea57068e99f4b3d9f9d8844f0926591 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment
por: Takuya Mizuno, et al.
Publicado: (2020) -
Transient third-degree atrioventricular block during anaesthesia in a cat
por: Hiroshi Sunahara, et al.
Publicado: (2021) -
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Naoya Maekawa, et al.
Publicado: (2021) -
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
por: Naoya Maekawa, et al.
Publicado: (2017) -
Systematic Identification of Endogenous Retroviral Protein-Coding Genes Expressed in Canine Oral Malignant Melanoma
por: Koichi Kitao, et al.
Publicado: (2021)